CRISPR-based genome editing has considerable therapeutic potential in a wide range of diseases 1,2,3,4,5. A key challenge is achieving efficient, clinically suitable delivery of genome editing ...
Higher-order structure is an important quality attribute of biosimilars that must be assessed by comparison to the reference licensed drug. To date, higher-order structure has been evaluated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback